UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 7, 2005
BIOPHAN TECHNOLOGIES, INC.
--------------------------------------------
(Exact name of registrant as specified in its charter)
NEVADA 0-26057 82-0507874
----------------------------- ------------- --------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
150 LUCIUS GORDON DRIVE, SUITE 215
WEST HENRIETTA, NEW YORK 14586
--------------------------------------- ---------
(Address of principal executive offices) (Zip code)
(585) 214-2441
-------------------------------
(Registrant's telephone number)
-2-
Item 7.01 Regulation FD Disclosure
In a press release dated January 7, 2005, the Company announced the signing of a
letter of intent to acquire an interest in AMRIS GmbH, a leading German-based
developer of MRI-safe and image-compatible technology solutions and biomedical
devices. As a part of the transaction, valued at approximately $4 million, the
Company will acquire worldwide exclusive rights to fifteen issued and pending
patents, important to the medical industry as the use of MRI interventional
medicine and MRI diagnostics for examination of stents and other implants
becomes standard medical procedure. See attached Exhibit 99.1 for the complete
text of the press release.
-3-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHAN TECHNOLOGIES, INC.
-----------------------------
(Registrant)
1/7/05 /S/ Robert J. Wood
Date ----------------- -----------------------------
(Signature)
Robert J. Wood
CFO, Treasurer, Secretary
(Principal Financial Officer)